Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Original source
Read on CointelegraphRelated market context
Strategy’s Michael Saylor commits to raising capital with STRC above par
Saylor's strategy could stabilize STRC's market value, ensuring consistent capital flow for Bitcoin investments, impacting crypto...
Coinbase Quantum Report Warns Millions Of Bitcoin Could Face Future Security Risks
TL;DR Coinbase’s Quantum Advisory Council published a report on post-quantum migration and abandoned coins. The report estimates t...
Anthropic’s dramatic model release strategy raises censorship risks, the shift to proprietary AI models is accelerating, and Chinese open source solutions are outperforming US counterparts | All-In Podcast
Chinese open source AI models surpass American counterparts, challenging global competitiveness and raising governance concerns. T...
Metaplanet to Launch Bitcoin Yield Products in Japan After $13 Million Siiibo Securities Deal
Metaplanet has agreed to acquire Siiibo Securities, a licensed Japanese Type I securities firm, as part of its Project Nova strate...
Bitcoin price faces new risk as big buyers lose conviction
Bitcoin’s largest buyers are no longer behaving like a reliable backstop for the largest cryptocurrency. The exchange-traded funds...
Still Adding Dots: Saylor Puts Bitcoin Bulls on Strategy Buy Watch
Michael Saylor’s latest orange-dot chart renewed speculation about another Strategy bitcoin buy as the company’s holdings reached...